Skip to Content
Søk Menu

ASCO20: What was the background and study design of the SPARTAN study?

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Relatert innhold

Daniel Heinrich

Utvalgte ESMO 2023 Høydepunkter: Prostatakreft

/ Daniel Heinrich
ProstatakreftESMO23 Play the Video 3:31
Henrik Grönberg

Prostate cancer: Adaptive, biomarker-driven platform trial shows that new hormonal agents have better efficacy for mCRPC

/ Henrik Grönberg
ProstatakreftESMO23 Play the Video 3:17
Fred Saad

Triplet therapy with darolutamide (DARO), androgen-deprivation therapy (ADT) and docetaxel (DOC) is a game changer in the treatment of metastatic hormone-sensitive prostate cancer

/ Fred Saad
ProstatakreftESMO23 Play the Video 3:17
Neal Shore

A long-term benefit of darolutamide for patients with nmCRPC

/ Neal Shore
ProstatakreftASCOGU23 Play the Video 4:50
Daniel Petrylak

Enfortumab vedotin as neoadjuvant treatment for MIBC

/ Daniel Petrylak
ProstatakreftASCOGU23 Play the Video 3:04
Ahmed Zedan

Inverse correlation between natural killer cell and treatment with enzalutamide

/ Ahmed H. Zedan
ProstatakreftASCOGU23 Play the Video 9:46
Simon Crabb

CAPItello-280 trial aims to confirm findings from ProCAID trial.

/ Simon Crabb
ProstatakreftASCOGU23 Play the Video 6:32

Darolutamide – A viable long-term treatment for nmCRPC

/ BestPractice Nordic
ProstatakreftASCOGU23
Daniel Heinrich

Prostatakreft – høydepunkter fra ESMO 2022

/ Daniel Heinrich
ProstatakreftESMO22 Play the Video 4:43
Back to top